Orphan drugs occupy a special place in the pharmaceutical industry and pharmacy practice in the US. Deriving their name from their forlorn economic condition, orphan drugs traditionally are those that are scientifically and technically capable of production, but are not economical to develop, test, and market. The social dilemma presented by these products is that although they may be fiscally unattractive, they may be extremely effective in treating devastating but rare diseases and conditions. Many eminent pharmacists have devoted their talents to dealing with the difficult issues involved with orphan drugs. One of the foremost experts in the area is Lawrence C. Weaver, PhD, Interim Dean and professor of the College of Pharmacy of the University of Minnesota. He and his associates have been active in this field for several years. For his work as a member of the International Health Advisory Panel, Weaver received the Food and Drug Administration (FDA) Commissioner's Special Citation for his efforts to "increase awareness in academic and business communities of the need to develop drugs to treat rare disease."! Compilations of orphan drugs and the disease entities with which they are identified are published regularly in two sources: (1) "The Cumulative List of Orphan Drug Products Designation and Approval," published periodically by the FDA, identifies the drugs and names the sponsors of orphan drug projects; (2) the USP 01 and its Updates provide an update published quarterly listing the latest information on orphan drugs and biologicals, including their designated use, dosage, forms and strengths (adult and pediatric), and comments. It also lists the sponsors' names and addresses.
How is it that orphan drugs playa role in today's dollar-conscious healthcare environment? Why do industry leaders continue to develop these limited market pharmaceuticals? The answer to these questions can be found, in large part, by looking at the efforts of the late Congressman Mickey Leland, the Texas legislator who died in an airplane crash while on a fact-finding mission in Africa.
No one, in my opinion, has contributed more in the last decade to the profession of pharmacy, nursing, and the public health than Congressman-Pharmacist Mickey Leland. Presented below is the evidence to prove the point.
Leland was a graduate of the Texas Southern University School of Pharmacy and was later elected to the US House of Representatives. In March 1983, while he was serving as Congressman from Texas, I interviewed him for Drug Intelligence and Clinical Pharmacu (DICP) regarding the Orphan Drug Bill, of which he was an original cosponsor. Leland said: I supported this important legislation for two major reasons. First, the pharmaceutical industry cannot reasonably be expected to develop drugs for which the sales demand, and hence the profitability, will be low and for which the cost of development is high. Speeding up the certification process and providing tax incentives to offset high development costs will encourage the development and production of orphan drugs.
Second, the quality of the health care available in this country must be judged by the degree to which we endeavor to make quality care available to the largest number of people. To those individuals stricken with a rare disease, efforts to encourage the development of orphan drugs are critical. We must ensure that orphan drugs and the treatment and hope they offer are developed and made available.'
In the same issue, DICP reported the following:
The Orphan Drug bill (HR 5238), signed into law (PL97-414) in January, provides tax breaks to pharmaceutical companies that engage in the research and development of drug products for those 2000 or so diseases for which no specific drug treatment is now available. In addition to the tax break (73 cents on each research dollar) to encourage research and development in this area, the new law finances a federal committee (Orphan Product Board, HHS) to coordinate such research and will place, in the FDA, the responsibility of cooperating with the drug industry on this matter. Diseases that, quite likely, will come into immediate review for drug research are Tourette syndrome, Parkinson's disease, neurofibromatosisdramatized by the play and movie ''The Elephant Man"cystic fibrosis, and multiple sclerosis.... As a practitionerof both pharmacy and law,Archambaultmaintained a private law practicefor six years and he practicedhospital pharmacy for 15years.He was a commissioned officer in the USPublicHealthService (USPHS) and was Directorof Pharmacyfor three years at the USPHS Hospital in Boston. He served for many years as chiefof the Phannacy Branch, Divisionof Hospitals,Bureauof Medical Services, USPHS, Washington, OC.
The listingof offices held by Archambaultin professional associations is extensive. Among them are the presidencies of both the AmericanPharmaceutical Association (APhA) and the AmericanSociety of HospitalPhannacists(ASHP). He was a memberof the USPharmacopeial Convention for more than 3 decadesand a trustee for 10 of thoseyears.
Among Archambault'smany honors, he receivedboth the RemingtonHonor Medal and the HAl<. WhitneyLectureAward, the highest honors by the APhA and the ASHP. He alsohasbeen awarded the highest honors by the USPHS, the Distinguished Service Medal,and by the Association of MilitarySurgeons,the Andrew CraigieAward.In 1972, the AmericanSociety of ConsultantPharmacists honoredArchambaultby establishing the GeorgeF.ArchambaultAnnual Awardand by naminghim its first recipient. This award, the highesthonor of that organization, is givenannuallyfor recognition of outstanding and meritoriouscontributions to thisspecialty. 
